Gene: Kcna4 (synonyms: Kv4, RK3, RHK1, Kv1.4) encodes a 655-amino-acid protein with six transmembrane domains (S1–S6) and a pore-forming region between S5–S6 .
Isoforms: Full-length recombinant Kcna4 (1-655 aa) and partial constructs are available, with purity ≥85% by SDS-PAGE .
| Host System | Purity | Applications | Source |
|---|---|---|---|
| E. coli | ≥85% | Structural studies, ELISA | |
| Mammalian cells | ≥85% | Functional assays, WB | |
| Cell-free systems | ≥85% | High-throughput screening |
Kcna4 encodes the α-subunit of Kv1.4 channels, mediating slowly inactivating transient outward K⁺ currents (I<sub>to,s</sub>) during cardiac action potential repolarization .
Knockout mice (Kv1.4<sup>−/−</sup>) show reduced I<sub>to</sub> current density, prolonging action potential duration .
Nucleoporin 50 (Nup50) binds the Kcna4 promoter via its FG-repeat domain, enhancing transcription and Kv1.4 protein expression in cardiomyocytes .
Overexpression of Nup50 increases I<sub>to,s</sub> current density by 77% (+70 mV; P<0.01) .
Kv1.4 channels associate with postsynaptic density protein 95 (PSD-95) in lipid rafts, modulating synaptic plasticity .
Cumulative inactivation properties (time constants: τ<sub>fast</sub> ≈ 200 ms; τ<sub>slow</sub> ≈ 2.5 s) influence neuronal firing patterns .
Antibody Validation: Anti-Kv1.4 monoclonal antibodies (e.g., K13/31, L71/5R) enable immunohistochemistry (IHC) and Western blotting .
Disease Modeling: Linked to microcephaly, cataracts, and dystonia in OMIM annotations .
Drug Development: Used to screen modulators of I<sub>to,s</sub> currents for arrhythmia therapies .